New lessons from the Alzheimer's disease neuroimaging initiative

Archives of Neurology

Volumn 68, Issue 1, 2011, Pages 19-21

  Salloway, Stephen ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TARENFLURBIL;

AGING; ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; COMBINATION CHEMOTHERAPY; DEMENTIA; DISEASE COURSE; EDITORIAL; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 78651327275     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.344     Document Type: Editorial

References (15)

1. Khachaturian ZS. Perspective on the Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):199-201.
2. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
3. Schneider LS, Insel PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68(1):58-66.
4. Salloway S, Sperling R, Gilman S, et al; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab inmild to moderate Alzheimer disease. Neurology. 2009;73(24):2061-2070.
5. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.
6. Green RC, Schneider LS, Amato DA, et al; Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302 (23):2557-2564.
7. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734-746.
8. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127.
9. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6(6):501-512.
10. Winblad B, Gauthier S, Scinto L, et al; GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70(22):2024-2035.
11. Petersen RC, Thomas RG, Grundman M, et al; Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
12. Salloway S, Ferris S, Kluger A, et al; Donepezil 401 Study Group. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63(4):651-657.
13. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009;72(18):1555-1561.
14. Seltzer B, Zolnouni P, Nunez M, et al; Donepezil "402" Study Group. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61(12):1852-1856.
15. A multicenter, double blind, placebo-controlled, safety and tolerability study of BMS- 708163 in patients with prodromal Alzheimer's disease. Clinical Trials Web site. http://clinicaltrials.gov/ct2/show/NCT00810147.Accessed November 15, 2010.